Amgen to Pay $71M to Settle Off-Label Enbrel, Aranesp Claims

California-based biotech Amgen has agreed to pay $71 million to resolve claims that the company promoted its popular Enbrel and Aranesp drugs for uses not approved by the FDA.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news